Small molecule · developed by Sunshine Lake Pharma Co.
HEC169096 is an orally administered agent studied in patients with advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05451602 | Phase 1/2 | Advanced Solid Tumor | Terminated | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →